HIGHLIGHTS
- who: The Oncologist et al. from the Department of Radiation Oncology, Heersink School of Medicine at University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA have published the research work: HiJAKing Immunotherapy-Resistant Melanoma for a Cure, in the Journal: (JOURNAL)
- what: The authors provide a on recent research endeavors concerning ICB resistance in melanoma patients. The authors demonstrate that loss of IFN-u03b3 signaling in melanoma hampers infiltration and functional rejuvenation of TILs, which in turn mediates ICB resistance.
SUMMARY
By releasing immune "brakes" (ie, CTLA-4, PD-1 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.